Recombinant Human LY6D Protein (HEK293)，mFc

LY6D is a member of the Ly6/uPAR protein family, characterized by the presence of a glycine-rich domain and a potential role in cell signaling and immune regulation. Research has gained momentum due to its involvement in various biological processes including cell adhesion, proliferation, and differentiation, as well as its implications in cancer biology and immune responses. The expression of LY6D is noted in certain hematopoietic cells and has been associated with the promotion of T cell activation and the regulation of the immune microenvironment. Notably, studies have highlighted its potential as a marker for specific T cell populations, which positions LY6D as a candidate for therapeutic targeting in immunotherapy. Given the increasing interest in understanding immune checkpoints and the complexities of tumor-immune interactions, LY6D's role in modulating these processes offers insight into novel treatment strategies. Consequently, research involving the recombinant expression of LY6D protein aims to elucidate its functional mechanisms, interactions with other immune regulators, and its potential utility as a biomarker or therapeutic target in various diseases, particularly in oncology. This represents a significant step toward comprehensively understanding how LY6D can be leveraged in the development of immunotherapeutic interventions.